Search Results

You are looking at 71 - 80 of 113 items for :

  • "consolidation therapy" x
  • Refine by Access: All x
Clear All
Full access

National Quality Measure Compliance for Palliative Bone Radiation Among Patients With Metastatic Non–Small Cell Lung Cancer

Stephen R. Grant, Benjamin D. Smith, Lauren E. Colbert, Qunyh-Nhu Nguyen, James B. Yu, Steven H. Lin, and Aileen B. Chen

therapy for painful osseous metastases . Pract Radiat Oncol 2020 ; 10 : e444 – 451 . 32289551 10.1016/j.prro.2020.03.008 16. Gomez DR , Tang C , Zhang J , et al. Local consolidative therapy vs. maintenance therapy or observation for

Full access

Acute Lymphoblastic Leukemia

Joseph C. Alvarnas, Patrick A. Brown, Patricia Aoun, Karen Kuhn Ballen, Naresh Bellam, William Blum, Michael W. Boyer, Hetty E. Carraway, Peter F. Coccia, Steven E. Coutre, Jennifer Cultrera, Lloyd E. Damon, Daniel J. DeAngelo, Dan Douer, Haydar Frangoul, Olga Frankfurt, Salil Goorha, Michael M. Millenson, Susan O'Brien, Stephen H. Petersdorf, Arati V. Rao, Stephanie Terezakis, Geoffrey Uy, Meir Wetzler, Andrew D. Zelenetz, Maoko Naganuma, and Kristina M. Gregory

-negative ALL can be further categorized as having high-risk disease, which may be particularly helpful when consolidation therapy with allogeneic HSCT is being considered. High risk is defined as having any of the following poor-risk factors: elevated WBC count

Full access

Biologic Agents in the Management of Hodgkin Lymphoma

Armin Rashidi and Nancy L. Bartlett

AETHERA study ( identifier: NCT01100502), evaluating BV as consolidation therapy after auto-SCT in high-risk patients. 40 Patients had primary refractory disease, or experienced disease relapse either less than 12 months after

Full access

Controversies Regarding Use of Myeloid Growth Factors in Leukemia

Jacqueline N. Poston and Pamela S. Becker

; 106 : 27 – 34 . 29. Heil G Hoelzer D Sanz MA . A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia . Blood 1997

Full access

Addition of Definitive Radiotherapy to Chemotherapy in Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer

Vivek Verma, Pamela K. Allen, Charles B. Simone II, Hiram A. Gay, and Steven H. Lin

2014 ; 32 : 3824 – 3830 . 11. Gomez DR Blumenschein GR Jr Lee JJ . Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first

Full access

Role of Alternative Donor Allogeneic Transplants in the Therapy of Acute Myeloid Leukemia

Hany Elmariah and Keith W. Pratz

Background For 40 years, standard therapy for acute myeloid leukemia (AML) has remained infusional cytarabine/anthracycline–based induction chemotherapy to achieve remission, followed typically by high-dose cytarabine consolidative therapy to

Full access

Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology

Daniel A. Pollyea, Jessica K. Altman, Rita Assi, Dale Bixby, Amir T. Fathi, James M. Foran, Ivana Gojo, Aric C. Hall, Brian A. Jonas, Ashwin Kishtagari, Jeffrey Lancet, Lori Maness, James Mangan, Gabriel Mannis, Guido Marcucci, Alice Mims, Kelsey Moriarty, Moaath Mustafa Ali, Jadee Neff, Reza Nejati, Rebecca Olin, Mary-Elizabeth Percival, Alexander Perl, Amanda Przespolewski, Dinesh Rao, Farhad Ravandi, Rory Shallis, Paul J. Shami, Eytan Stein, Richard M. Stone, Kendra Sweet, Swapna Thota, Geoffrey Uy, Pankit Vachhani, Carly J. Cassara, Deborah A. Freedman-Cass, and Katie Stehman

options include low-intensity therapy with venetoclax-based regimens, steroids, and supportive care. Postremission Surveillance for BPDCN Following completion of consolidation therapy, it is recommended to monitor a CBC, including platelets

Full access

Hematopoietic Progenitor Cell Transplantation in Children, Adolescents, and Young Adults With Relapsed Mature B-Cell NHL

Aliza Gardenswartz and Mitchell S. Cairo

‐cell non Hodgkin lymphoma [abstract] . Br J Haematol 2018 ; 182 ( Suppl 1 ): Abstract 28 . 25. Moskowitz CH , Nademanee A , Masszi T , . Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with

Full access

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018

Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Philippe Armand, Celeste M. Bello, Cecil M. Benitez, Philip J. Bierman, Robert Chen, Bouthaina Dabaja, Robert Dean, Andres Forero, Leo I. Gordon, Francisco J. Hernandez-Ilizaliturri, Ephraim P. Hochberg, Jiayi Huang, Patrick B. Johnston, Mark S. Kaminski, Vaishalee P. Kenkre, Nadia Khan, Kami Maddocks, David G. Maloney, Monika Metzger, Joseph O. Moore, David Morgan, Craig H. Moskowitz, Carolyn Mulroney, Rachel Rabinovitch, Stuart Seropian, Randa Tao, Jane N. Winter, Joachim Yahalom, Jennifer L. Burns, and Ndiya Ogba

Oncol 2018 ; 19 : 257 – 266 . 57. Moskowitz CH Nademanee A Masszi T . Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a

Full access

Non-Hodgkin’s Lymphomas, Version 4.2014

Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, and Hema Sundar

rituximab. First-Line Consolidation Therapy: HDT/ASCR as first-line consolidation has shown promising outcomes in multiple studies. 42 - 48 In a prospective study of sequential front-line CHOP/DHAP followed by HDT/ASCR in patients with MCL (n=28; n=23